Cellport Software — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

CellPort Software offers a specialized SaaS platform that digitizes and centralizes the complex workflows of cell manufacturing and banking. Founded in 2014 and headquartered in Boulder, Colorado, the company targets the growing need for standardization, traceability, and efficiency in cell-based R&D and production. Its platform features digital protocols, resource tracking, in-app messaging, and customized reporting to help labs transition from research to GMP manufacturing. As a private company, CellPort operates in the digital lab management space, competing by providing an integrated solution for a historically manual and fragmented process.

Digital HealthAI / Machine Learning

Technology Platform

An all-in-one SaaS platform for digital lab management, specializing in cell culturing, cell banking, bioprocessing, and resource tracking. It features digital protocols/electronic batch records, in-app messaging, and customized reporting for compliance.

Opportunities

The rapid growth of cell and gene therapies, biologics, and cellular agriculture is driving demand for specialized, scalable digital tools to manage complex cell-based workflows.

The industry-wide shift towards digital 'Labs of the Future' and increased regulatory emphasis on data integrity and traceability creates a strong tailwind for compliant SaaS platforms like CellPort.

Risk Factors

CellPort faces competition from both large, established lab software vendors and newer startups, risking market displacement.

Long sales cycles and high validation hurdles in regulated pharma and biotech environments can slow customer acquisition and revenue growth.

The company also bears execution risk in maintaining a secure, reliable, and seamlessly integrated platform.

Competitive Landscape

CellPort competes in the digital lab management space, facing competition from broad Laboratory Information Management Systems (LIMS) and Manufacturing Execution Systems (MES) providers like Thermo Fisher and Siemens, as well as from newer electronic lab notebook (ELN) and workflow automation startups. Its differentiation is its specialized focus on end-to-end cell culture and banking operations, a niche not fully addressed by generalized solutions.

More companies in Digital Health & Biotech SaaS →More companies in United States →